149 related articles for article (PubMed ID: 9353575)
21. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
Hutt V; Bonn R; Fritschi E; Jaeger H
Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
[TBL] [Abstract][Full Text] [Related]
23. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
Menke G; Schnellhammer R; Rietbrock N
Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
[TBL] [Abstract][Full Text] [Related]
25. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
Straehl P; Galeazzi RL
Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
Schaumann W
Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
[TBL] [Abstract][Full Text] [Related]
27. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Niopas I; Daftsios AC; Nikolaidis N
Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion.
Bergami A; Bernasconi R; Caccia S; Leopaldi D; Mizrahi J; Sardina M; Urso R; Warrington SJ; Latini R
J Clin Pharmacol; 1997 Sep; 37(9):828-33. PubMed ID: 9549637
[TBL] [Abstract][Full Text] [Related]
29. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
30. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
Yang LL; Yuan YS; Zhao FL
Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
[TBL] [Abstract][Full Text] [Related]
31. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Halkin H; Almog S; Friedman E
Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
[TBL] [Abstract][Full Text] [Related]
32. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
Baxter T; Eadie CJ
Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
[TBL] [Abstract][Full Text] [Related]
33. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
Laufen H; Aumann M; Leitold M
Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
[TBL] [Abstract][Full Text] [Related]
34. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
Johnson KI; Gladigau V; Schnelle K
Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Luo WX; Zhang YD; Shen JP; Ding Y; Huang DK; Luo JP; Qiu J; Jiang ZH; Peng JH; Sheng LS
Zhongguo Yao Li Xue Bao; 1999 Oct; 20(10):951-6. PubMed ID: 11270999
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the time to onset of action on myocardial ischaemia following intravenous administration of isosorbide dinitrate and 5-isosorbide mononitrate in Chinese patients.
Wu ZG; Li JN; Fan M; Shang YK; Zhang YW; Bai J; Ding R; Cheng JM; Liang C
Arzneimittelforschung; 2004; 54(5):275-9. PubMed ID: 15212189
[TBL] [Abstract][Full Text] [Related]
38. Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.
Schneider W; Menke G; Heidemann R; Satter P; Kaltenbach M; Rietbrock N
Eur J Clin Pharmacol; 1990; 38(2):145-7. PubMed ID: 2338111
[TBL] [Abstract][Full Text] [Related]
39. Influence of electric foot shock on pharmacokinetics of isosorbide dinitrate orally administered to rats.
Gomita Y; Furuno K; Araki Y
Jpn J Pharmacol; 1989 Feb; 49(2):297-9. PubMed ID: 2733266
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of isosorbide mononitrate.
Abshagen UW
Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
